drugset / Trial / NCT02293564

Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the Hand

NCT02293564

Completed 312 enrolled XOMA (US) LLC
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety of gevokizumab in the treatment of active inflammatory, erosive osteoarthritis of the hand.

Timeline

Start
2013-03
Primary completion
2015-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject gevokizumab Monoclonal antibody Subcutaneous

Indications